CYP2C19 genotype is associated with symptomatic recurrence of GERD during maintenance therapy with low-dose lansoprazole

European Journal of Clinical Pharmacology

Volumn 65, Issue 7, 2009, Pages 693-698

  Furuta, Takahisa ^a   Sugimoto, Mitsushige ^a   Kodaira, Chise ^a   Nishino, Masafumi ^a   Yamade, Mihoko ^a   Ikuma, Mutsuhiro ^a   Shirai, Naohito ^b   Watanabe, Hiroshi ^a   Umemura, Kazuo ^a   Kimura, Michio ^a   Hishida, Akira ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Enshu General Hospital   (Japan)

Author keywords

CYP2C19; GERD; Lansoprazole

Indexed keywords

CYTOCHROME P450 2C19; LANSOPRAZOLE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; ESOPHAGOSCOPY; ESOPHAGUS MUCOSA; FEMALE; GASTROESOPHAGEAL REFLUX; GENETIC ASSOCIATION; GENOTYPE; HUMAN; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENT DISEASE; RISK ASSESSMENT; TREATMENT DURATION;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; AGED; ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTROESOPHAGEAL REFLUX; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; RECURRENCE;

EID: 67649121827     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-009-0628-5     Document Type: Article

References (39)

1. OT Nebel MF Fornes DO Castell 1976 Symptomatic gastroesophageal reflux: incidence and precipitating factors Am J Dig Dis 21 11 953 956
2. H Yamagishi T Koike S Ohara 2008 Prevalence of gastroesophageal reflux symptoms in a large unselected general population in Japan World J Gastroenterol 14 9 1358 1364
3. N Vakil SV van Zanten P Kahrilas J Dent R Jones 2006 The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus Am J Gastroenterol 101 8 1900 1920
4. J Dent 1994 Roles of gastric acid and pH in the pathogenesis of gastro-oesophageal reflux disease Scand J Gastroenterol Suppl 201 55 61 (Pubitemid 24165477)
5. SJ Sontag BI Hirschowitz S Holt 1992 Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: the U.S. Multicenter Study Gastroenterology 102 1 109 118
6. DJ Hetzel J Dent WD Reed 1988 Healing and relapse of severe peptic esophagitis after treatment with omeprazole Gastroenterology 95 4 903 912 (Pubitemid 18235531)
7. M Tebaldi RC Heading 1998 Quality of life assessment in reflux disease Eur J Gastroenterol Hepatol 10 6 451 454 (Pubitemid 28306534)
8. DA Johnson SB Benjamin NB Vakil 2001 Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety Am J Gastroenterol 96 1 27 34 (Pubitemid 32104803)
9. G Tytgat 2006 Long-term GERD management: the individualized approach Drugs Today (Barc) 42 Suppl B 23 29 (Pubitemid 46422080)
10. GN Tytgat K McColl J Tack 2008 New algorithm for the treatment of gastro-oesophageal reflux disease Aliment Pharmacol Ther 27 3 249 256
11. S Mine T Iida T Tabata H Kishikawa Y Tanaka 2005 Management of symptoms in step-down therapy of gastroesophageal reflux disease J Gastroenterol Hepatol 20 9 1365 1370 (Pubitemid 43960833)
12. K Lauritsen J Deviere MA Bigard 2003 Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results Aliment Pharmacol Ther 17 3 333 341 (Pubitemid 36259395)
13. T Furuta N Shirai M Sugimoto K Ohashi T Ishizaki 2004 Pharmacogenomics of proton pump inhibitors Pharmacogenomics 5 2 181 202 (Pubitemid 38351277)
14. S Shi U Klotz 2008 Proton pump inhibitors: an update of their clinical use and pharmacokinetics Eur J Clin Pharmacol 64 10 935 951
15. T Furuta N Shirai F Watanabe 2002 Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole Clin Pharmacol Ther 72 4 453 460 (Pubitemid 35178870)
16. M Kawamura S Ohara T Koike 2003 The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism Aliment Pharmacol Ther 17 7 965 973 (Pubitemid 36459609)
17. M Miura H Tada N Yasui-Furukori 2004 Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes Eur J Clin Pharmacol 60 9 623 628 (Pubitemid 40064594)
18. M Kawamura S Ohara T Koike 2007 Cytochrome P450 2C19 polymorphism influences the preventive effect of lansoprazole on the recurrence of erosive reflux esophagitis J Gastroenterol Hepatol 22 2 222 226 (Pubitemid 46181352)
19. D Armstrong JR Bennett AL Blum 1996 The endoscopic assessment of esophagitis: a progress report on observer agreement Gastroenterology 111 1 85 92 (Pubitemid 26226887)
20. EJ Kuipers L Lundell EC Klinkenberg-Knol 1996 Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication N Engl J Med 334 16 1018 1022 (Pubitemid 26123777)
21. T Furuta Y Sagehashi N Shirai 2005 Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H. pylori infection Clin Gastroenterol Hepatol 3 6 564 573 (Pubitemid 40824749)
22. A Ishiguro T Kubota Y Soya 2005 High-throughput detection of multiple genetic polymorphisms influencing drug metabolism with mismatch primers in allele-specific polymerase chain reaction Anal Biochem 337 2 256 261 (Pubitemid 40187252)
23. SC Sim C Risinger ML Dahl 2006 A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants Clin Pharmacol Ther 79 1 103 113 (Pubitemid 43069582)
24. M Kimura S Tani H Watanabe 2008 High speed clinical data retrieval system with event time sequence feature Methods Inf Med 47 6 560 568
25. T Joh H Miwa K Higuchi 2007 Validity of endoscopic classification of nonerosive reflux disease J Gastroenterol 42 6 444 449 (Pubitemid 47050006)
26. T Furuta N Shirai M Sugimoto A Nakamura A Hishida T Ishizaki 2005 Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies Drug Metab Pharmacokinet 20 3 153 167
27. T Shimatani M Inoue T Kuroiwa 2006 Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19 Clin Pharmacol Ther 79 1 144 152 (Pubitemid 43069585)
28. NJ Bell D Burget CW Howden J Wilkinson RH Hunt 1992 Appropriate acid suppression for the management of gastro-oesophageal reflux disease Digestion 51 Suppl 1 59 67
29. RH Hunt 1999 Importance of pH control in the management of GERD Arch Intern Med 159 7 649 657 (Pubitemid 29177653)
30. RM Baldwin S Ohlsson RS Pedersen 2008 Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers Br J Clin Pharmacol 65 5 767 774
31. Wang G, Lei HP, Li Z et al (2008) The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers. Eur J Clin Pharmacol Epub (2008/11/05)
32. M Kurzawski B Gawronska-Szklarz J Wrzesniewska A Siuda T Starzynska M Drozdzik 2006 Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients Eur J Clin Pharmacol 62 10 877 880 (Pubitemid 44521437)
33. K Sugimoto T Uno H Yamazaki T Tateishi 2008 Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population Br J Clin Pharmacol 65 3 437 439 (Pubitemid 351316919)
34. T Furuta M Sugimoto C Kodaira 2007 The influence of the CYP2C19*17 allele on the eradication rates of H-pylori by a triple therapy with lamsoprazole, clarithromycin and amoxicillin in Japan Gastroenterology 132 4 A612 A612
35. T Furuta N Shirai M Kodaira 2007 Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori Clin Pharmacol Ther 81 4 521 528 (Pubitemid 46452299)
36. M Sugimoto T Furuta N Shirai 2004 Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status Clin Pharmacol Ther 76 4 290 301 (Pubitemid 39313119)
37. N Shirai T Furuta F Xiao 2002 Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups Aliment Pharmacol Ther 16 4 837 846 (Pubitemid 34407534)
38. I Ieiri Y Kishimoto H Okochi 2001 Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism Eur J Clin Pharmacol 57 6-7 485 492
39. HL Qiao YR Hu X Tian 2006 Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype Eur J Clin Pharmacol 62 2 107 112